#Italy #Florence #A. Menarini #Sinocare #CGM System

A. Menarini Diagnostics and Sinocare Forge Exclusive Partnership

In a landmark development for diabetes management, A. Menarini Diagnostics has announced an exclusive distribution agreement with Sinocare for their state-of-the-art continuous glucose monitoring (CGM) system. This innovative technology will cater to the growing demand for advanced diabetes care, particularly across Europe.

This exclusive collaboration allows A. Menarini Diagnostics to register, promote, distribute, and commercially market Sinocare's cutting-edge third-generation CGM system in over 20 European markets. This significant step is expected to enhance accessibility to essential diabetes management tools for patients across the continent.

Significance of the Partnership

According to Dr. Jiangfeng Fei, the head of Sinocare’s CGM business division, this partnership marks a critical milestone in their mission to expand access to their third-generation CGM systems. “By joining forces with A. Menarini Diagnostics, an industry leader in healthcare, we aim to make this innovative diabetes management technology available to a wider audience,” he stated.

A. Menarini Diagnostics has reiterated their commitment to delivering innovative healthcare solutions. Fabio Piazzalunga, the company’s General Manager and Global Director, expressed enthusiasm for the prospects of this agreement, highlighting that securing exclusive rights to distribute and market Sinocare’s CGM system aligns with their goal of enhancing healthcare standards.

Expanding Healthcare Options

Utilizing A. Menarini's extensive network and industry expertise, both companies intend to ensure that the advanced features of Sinocare’s CGM systems reach individuals who stand to benefit the most from enhanced diabetes management. The partnership is poised to significantly boost the availability of this next-gen technology, responding to a crucial need in diabetes treatment spaces.

About A. Menarini Diagnostics

A. Menarini Diagnostics is a prominent player in the healthcare sector, dedicated to delivering innovative healthcare solutions that yield better health outcomes. With over 45 years of experience in offering advanced diagnostic tools, the company is committed to improving the quality of life worldwide. A division of the Menarini Group established in 1886, it currently operates in 140 countries and employs over 17,000 staff with a turnover of 4.375 billion euros in 2023.

About Sinocare

Sinocare is recognized as Asia’s largest glucose monitoring device manufacturer, originally founded in 2002. It was the first blood glucose meter company to be publicly listed in China. With a commercial footprint that reaches Asia, Europe, and North America, Sinocare has internationalized through both partnerships and acquisitions. Their dedication to innovation has elevated them to become the fourth-largest manufacturer of blood glucose meters globally and a leading company in the point-of-care testing (POCT) sector.

This partnership between A. Menarini Diagnostics and Sinocare is a promising development in the continuous effort to innovate diabetes care, ensuring that life-enhancing technology is both accessible and effective for those living with diabetes.